Next Article in Journal
Thioredoxin and Cancer: A Role for Thioredoxin in all States of Tumor Oxygenation
Next Article in Special Issue
Modulation of Radiation-Induced Genetic Damage by HCMV in Peripheral Blood Lymphocytes from a Brain Tumor Case-Control Study
Previous Article in Journal
Biology of Human Cutaneous Melanoma
Previous Article in Special Issue
Overexpression of Periostin and Lumican in Esophageal Squamous Cell Carcinoma
Cancers 2010, 2(1), 190-208; doi:10.3390/cancers2010190

Cancer Biomarkers: Are We Ready for the Prime Time?

 and 2,,*
Received: 20 February 2010 / Revised: 2 March 2010 / Accepted: 19 March 2010 / Published: 22 March 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
View Full-Text   |   Download PDF [202 KB, uploaded 22 March 2010]   |   Browse Figure
Abstract: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. In cancer, a biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker might be either a molecule secreted by a tumor or it can be a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis and epidemiology. These markers can be assayed in non-invasively collected biofluids. However, few cancer biomarkers are highly sensitive and specific for cancer detection at the present time. Consequently, biomarkers are not yet ready for routine use due to challenges in their clinical validation for early disease detection, diagnosis and monitoring to improve long-term survival of patients.
Keywords: biomarker; cancer; diagnosis; glycans; prognosis; validation biomarker; cancer; diagnosis; glycans; prognosis; validation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Mishra, A.; Verma, M. Cancer Biomarkers: Are We Ready for the Prime Time? Cancers 2010, 2, 190-208.

AMA Style

Mishra A, Verma M. Cancer Biomarkers: Are We Ready for the Prime Time? Cancers. 2010; 2(1):190-208.

Chicago/Turabian Style

Mishra, Alok; Verma, Mukesh. 2010. "Cancer Biomarkers: Are We Ready for the Prime Time?" Cancers 2, no. 1: 190-208.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert